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Percutaneous aortic valve
replacement with the CoreValve
bioprosthesis
To the Editor:
We read with interest the recent article by
Marcheix and colleagues1 in the Journal
dealing with percutaneous aortic valve im-
plantation. They reported their experience
using the second generation (21F) of the
CoreValve prosthesis (CoreValve, Inc, Paris,
France) in 10 consecutive high-risk surgical
patients (median logistic EuroSCORE of
32%). The prosthesis was successfully deliv-
ered in all cases, with a doubling of the aortic
valve area (from 0.57 6 0.19 to 1.2 6 0.35
cm2) and a significant decrease in transvalv-
ular gradient.
We would like to comment on these re-
sults and also ask for some clarifications
regarding their data:
Prosthesis sizing is an important issue.
On one hand, undersizing may be responsi-
ble for valve migration (owing to poor
anchoring), perivalvular leak, or patient–
prosthesis mismatch. On the other hand,
oversizing may theoretically lead to coro-
nary obstruction or favor atrioventricular
block. There is actually only one available
size of the CoreValve prosthesis, with
a 21-mm bioprosthesis implanted within
the stent frame. This valve is at the present
time indicated when the aortic annulus
diameter ranges from 20 to 27 mm.2 Al-
though the authors did not report the annu-
lus size in their group of patients, we do
not understand how proper sizing could be
achieved with a single-sized bioprosthesis.
Aortic bicuspidy is observed in half of
cases of severe aortic stenosis.3 In our expe-
rience, misdeployment of a valved stent is
likely to occur within a bicuspid aortic
valve,4,5 which may alter its long-term dura-
bility. Did the authors face a case with
a bicuspid aortic valve or have they system-
atically preoperatively screened the patients
and excluded for the endovascular proce-
dure those with a bicuspid aortic valve?
Letters to the EditorReply to the Editor:
We thank Drs Di Marco and Gerosa for con-
sidering that injection of mesenchymal stem
cells (MSCs) in decellularized scaffolds be-
fore in vivo implantation represents an inno-
vative concept in the valvular field, and we
completely agree that this concept requires
a careful validation. However, they ex-
pressed some concern about our conclusion
that bone marrow–derived mononuclear cell
injection induced a structural deterioration
of the scaffold and that MSCs induced a pro-
tective effect.
We believe that the observation of a del-
eterious effect of bone marrow–derived
mononuclear cells is an interesting point
because these cells had never been tested
in the field of valve tissue engineering,
whereas they are currently used in clinical
assays in the field of myocardial failure.
Also, we agree that endothelialization and
scaffold recolonization are 2 distinct pro-
cesses that do not always take place
together. However, Bertiplaglia and col-
leagues1 have demonstrated that 2 weeks
after in vitro interstitial cell seeding into
decellularized leaflets, grafted cells were
found penetrating the decellularized scaf-
fold and expressed various immunologic
differentiation patterns, such as fibroblasts,
myofibroblasts, smooth muscle cells, andalso endothelial cells. Similarly, we observed
a significant recolonization after injection of
MSCs, and moreover, as stated in our arti-
cle, pulmonary leaflets exhibited a typical
organization in 3 layers (ie, fibrosa, spon-
giosa, and ventricularis) in each animal of
the MSC group.2
Finally, several lines of evidence indi-
cate that in vivo recellularization of valve
scaffolds is no longer a ‘‘nonvalidated
route.’’ In a previous work we demon-
strated evidence of spontaneous recellulari-
zation of a decellularized valve.3 Such
results were emphasized by Dohmen and
coworkers4 comparing in vitro seeded and
nonseeded valves implanted in sheep. After
6 months, valves from both groups ex-
hibited full recolonization of the leaflets,
with comparable hemodynamic behavior
and valve remodeling.
We recognize that further studies are
needed to compare spontaneous recoloniza-
tion of an appropriated scaffold and the ef-
fects of in situ injection of autologous cells.
Also, we have to investigate how injected
autologous MSCs improve in situ recoloni-
zation by myofibroblasts and endothelial
cells or improve host cell migration. How-
ever, the challenge seems now to understand
and to favor in vivo, rather than in vitro,
valve scaffold recolonization.
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